Showing results (51-60 of 243) with videos related to
Sort By:
Pageof 25
Proteomics|September 8, 2004
Proteomic signature of human cancer cellsMasahiro Seike, Tadashi Kondo, Kazuyasu Fujii, et al.Internal Medicine (Tokyo, Japan)|October 15, 2025
A Case of Drug-induced Interstitial Lung Disease with a Hypersensitivity Pneumonitis Pattern Following Pembrolizumab plus Epirubicin and Cyclophosphamide Therapy: First Report with Pathological FindingsShota Kaburaki, Toru Tanaka, Koichiro Kamio, et al.Oncotargets and Therapy|September 5, 2024
Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case SeriesKaoruko Shimbu, Kakeru Hisakane, Naohiro Kadoma, et al.Respiratory Medicine|August 20, 2023
Minimal effective dose of maintenance steroid therapy for relapse of cryptogenic organizing pneumoniaKenichiro Atsumi, Kakeru Hisakane, Erika Mikami, et al.International Journal of Clinical Oncology|November 30, 2023
Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapyYuto Terashima, Taiki Hakozaki, Yuji Uehara, et al.Journal of Thoracic Disease|May 13, 2024
Compatible with fibrotic hypersensitivity pneumonitis on high-resolution computed tomography: from the ATS/JRS/ALAT 2020 hypersensitivity pneumonitis guidelinesShota Kaburaki, Ryo Okuda, Tamiko Takemura, et al.International Journal of Chronic Obstructive Pulmonary Disease|March 25, 2026
Difference in Respiratory Function Between GOLD Stage 1 and Preserved Ratio Impaired Spirometry as Assessed by Impulse Oscillometry and SpirometryAyumi Shimizu, Mitsunori Hino, Kaoru Kubota, et al.Future Oncology (London, England)|November 11, 2021
First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance statusShigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, et al.Medical Molecular Morphology|March 27, 2007
Xanthoma tissue-extracted LDL density substances are the main inducer of myelin-like bodies and ceroid granules in foam cellsKimiko Nakajima, Mitsunori Ikeda, Ken-Ichi Yagyu, et al.Anticancer Research|February 4, 2019
Tenascin XB Is a Novel Diagnostic Marker for Malignant MesotheliomaKoji Nakayama, Masahiro Seike, Rintaro Noro, et al.Pageof 25